25th Feb 2019 08:38
LONDON (Alliance News) - FTSE 100-listed drugmaker AstraZeneca PLC said Monday its late phase clinical trial for its blockbuster Brilinta cardiovascular drug had met its primary endpoint.
The Phase III THEMIS clinical trial saw Brilinta - the brand name of ticagrelor - show a "statistically-significant reduction in a composite of major adverse cardiovascular events" when taken alongside aspirin. This is in contrast to taking aspirin alone.
The THEMIS trial - started in early 2014 - included 19,000 patients across 42 countries with coronary artery disease and type-two diabetes who had no history of heart attack or stroke.
AstraZeneca Vice President & Global Medicines Development Unit Head Elizabeth Bjork said: "Approaches to help reduce cardiovascular morbidity further in patients with coronary artery disease and type-2 diabetes are urgently needed. The positive result from the THEMIS trial may offer a potential benefit for this high-risk patient population."
Shares in AstraZeneca were 0.3% higher at 6,178.00 pence on Monday.
Related Shares:
Astrazeneca